Results from our study together with these previous reports confirm that TNFRSF9 is associated with the activation of TI-Tregs, and their inhibition may boost anticancer treatments including lung cancer immunotherapy by reducing immune suppressive function of Tregs in tumor. This evidence concerns the gene TNFRSF9 and lung cancer.